Medications for T-Cell Lymphoma
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in T-Cell Lymphoma.
Found 16 Approved Drugs for T-Cell Lymphoma
Adcetris
Generic Name
Brentuximab Vedotin
Adcetris
Generic Name
Brentuximab Vedotin
Form: Injection
Method of administration: Intravenous
FDA approval date: August 25, 2011
Classification: CD30-directed Immunoconjugate
ADCETRIS is a CD30-directed antibody and microtubule inhibitor conjugate indicated for treatment of: Adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vinblastine, and dacarbazine.
Istodax
Generic Name
RomiDEPsin
Istodax
Generic Name
RomiDEPsin
Form: Kit
FDA approval date: January 04, 2010
Romidepsin for injection is indicated for the treatment of cutaneous T-cell lymphoma (CTCL) in adult patients who have received at least one prior systemic therapy. Romidepsin for injection is a histone deacetylase (HDAC) inhibitor indicated for the treatment of cutaneous T-cell lymphoma (CTCL) in adult patients who have received at least one prior systemic therapy ( 1 ).
Targretin
Generic Name
Bexarotene
Targretin
Generic Name
Bexarotene
Form: Capsule, Gel
Method of administration: Oral, Topical
FDA approval date: December 29, 1999
Classification: Retinoid
Bexarotene capsules are indicated for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy. Bexarotene is a retinoid indicated for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy. ( 1 )
Valchlor
Generic Name
Mechlorethamine
Valchlor
Generic Name
Mechlorethamine
Form: Gel
Method of administration: Topical
FDA approval date: November 08, 2018
Classification: Alkylating Drug
VALCHLOR is indicated for the topical treatment of Stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received prior skin-directed therapy. VALCHLOR is an alkylating drug indicated for the topical treatment of Stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received prior skin-directed therapy ( 1 ).
Zolinza
Generic Name
Vorinostat
Zolinza
Generic Name
Vorinostat
Form: Capsule
Method of administration: Oral
FDA approval date: October 06, 2006
Classification: Histone Deacetylase Inhibitor
ZOLINZA ® is indicated for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, persistent or recurrent disease on or following two systemic therapies. ZOLINZA is a histone deacetylase (HDAC) inhibitor indicated for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistent or recurrent disease on or following two systemic therapies. ( 1 )
Showing 1-5 of 16
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances